Subcutaneous versus intravenous amivantamab, both in combination with lazertinib, in refractory EGFR-mutated non-small cell lung cancer: Patient satisfaction and resource utilization results from the PALOMA-3 study.

Alexander M, Cheng Y, Lee SH, Passaro A, Spira AI, Cho BC, Lim SM, Ohe Y, Nagrial A, Tan JL, Wainsztein V, Ramos E, Campelo MDRG, Akamatsu H, Nguyen D, Cortot AB, Zer A, Erdem D, Sanborn RE, Emde TO, Minchom AR, Zurawski B, Ferreira ML, Yang JC, Marmarelis ME, Schuchard J, Alves J, Ghosh D, Balaburski G, Verheijen RB, Ribeiro L, Gamil M, Bauml JM, Baig M, Leighl NB

Open source

DOI: 10.1016/j.ejca.2025.115624
Published: 2025 Sep 9
Container: European journal of cancer (Oxford, England : 1990)
Publisher: Not recorded
Open access: unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/j.ejca.2025.115624,
  title = {Subcutaneous versus intravenous amivantamab, both in combination with lazertinib, in refractory EGFR-mutated non-small cell lung cancer: Patient satisfaction and resource utilization results from the PALOMA-3 study.},
  author = {Alexander M and Cheng Y and Lee SH and Passaro A and Spira AI and Cho BC and Lim SM and Ohe Y and Nagrial A and Tan JL and Wainsztein V and Ramos E and Campelo MDRG and Akamatsu H and Nguyen D and Cortot AB and Zer A and Erdem D and Sanborn RE and Emde TO and Minchom AR and Zurawski B and Ferreira ML and Yang JC and Marmarelis ME and Schuchard J and Alves J and Ghosh D and Balaburski G and Verheijen RB and Ribeiro L and Gamil M and Bauml JM and Baig M and Leighl NB},
  year = {2025},
  journal = {European journal of cancer (Oxford, England : 1990)},
  doi = {10.1016/j.ejca.2025.115624},
  url = {https://doi.org/10.1016/j.ejca.2025.115624}
}

RIS

TY  - JOUR
TI  - Subcutaneous versus intravenous amivantamab, both in combination with lazertinib, in refractory EGFR-mutated non-small cell lung cancer: Patient satisfaction and resource utilization results from the PALOMA-3 study.
AU  - Alexander M
AU  - Cheng Y
AU  - Lee SH
AU  - Passaro A
AU  - Spira AI
AU  - Cho BC
AU  - Lim SM
AU  - Ohe Y
AU  - Nagrial A
AU  - Tan JL
AU  - Wainsztein V
AU  - Ramos E
AU  - Campelo MDRG
AU  - Akamatsu H
AU  - Nguyen D
AU  - Cortot AB
AU  - Zer A
AU  - Erdem D
AU  - Sanborn RE
AU  - Emde TO
AU  - Minchom AR
AU  - Zurawski B
AU  - Ferreira ML
AU  - Yang JC
AU  - Marmarelis ME
AU  - Schuchard J
AU  - Alves J
AU  - Ghosh D
AU  - Balaburski G
AU  - Verheijen RB
AU  - Ribeiro L
AU  - Gamil M
AU  - Bauml JM
AU  - Baig M
AU  - Leighl NB
PY  - 2025
JO  - European journal of cancer (Oxford, England : 1990)
DO  - 10.1016/j.ejca.2025.115624
UR  - https://doi.org/10.1016/j.ejca.2025.115624
ER  -

APA

M, A., Y, C., SH, L., A, P., AI, S., BC, C., SM, L., Y, O., A, N., JL, T., V, W., E, R., MDRG, C., H, A., D, N., AB, C., A, Z., D, E., RE, S., TO, E., AR, M., B, Z., ML, F., JC, Y., ME, M., J, S., J, A., D, G., G, B., RB, V., L, R., M, G., JM, B., M, B., & NB, L. (2025). Subcutaneous versus intravenous amivantamab, both in combination with lazertinib, in refractory EGFR-mutated non-small cell lung cancer: Patient satisfaction and resource utilization results from the PALOMA-3 study.. European journal of cancer (Oxford, England : 1990). https://doi.org/10.1016/j.ejca.2025.115624

Source records

pubmed · retrieved 2026-09-26T05:00:48.625Z